Celularity Stock Surges Over 8% Amid Florida Stem Cell Policy, New Partnership Boost

Celularity Inc. (CELU) saw an 8.04% rise in pre-market hours on Tuesday, following a change in Florida law allowing certain stem cell therapies without FDA approval. The company also announced a partnership with Fountain Life to supply stem cell therapy products. CELU's market cap stands at $53.65 million, with an average volume of 71,080 shares.

Celularity Inc. (CELU), a biotechnology company based in the United States, saw an 8.04% rise in its stock value in the pre-market hours on Tuesday. The stock closed at $2.42, up from $2.24 on Monday, marking a 6.16% increase [2].

The surge in CELU's stock price can be attributed to a change in Florida law that allows certain stem cell therapies without US Food and Drug Administration (FDA) approval. This regulatory shift has created an opportunity for Celularity to expand its offerings and meet the increased demand for stem cell treatments [1].

Additionally, Celularity announced a partnership with Fountain Life to supply stem cell therapy products. This partnership, announced on July 9, is expected to have a positive impact on the company's stock value [2].

Despite the recent surge, CELU's stock has experienced a significant decrease from its year-to-date high of $5.22. The company's market cap currently stands at $53.65 million, with an average volume of 71,080 shares [2].

The positive momentum in CELU's stock is evident, with the stock faring well across all time frames according to Benzinga's Edge Stock Rankings. However, investors should remain vigilant and consider the potential risks and opportunities associated with the company's growth prospects and regulatory environment.

References:
[1] https://stockstotrade.com/news/celularity-inc-celu-news-2025_07_15/
[2] https://www.benzinga.com/markets/equities/25/07/46410366/celularity-inc-surges-over-8-pre-market-amid-florida-stem-cell-policy-new-partnership-boost